.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Mallinckrodt
Merck
UBS
AstraZeneca
Chinese Patent Office
Julphar
Cerilliant
Medtronic
Teva

Generated: November 22, 2017

DrugPatentWatch Database Preview

Kai Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for KAI PHARMS INC, and when can generic versions of KAI PHARMS INC drugs launch?

KAI PHARMS INC has one approved drug.

There are four US patents protecting KAI PHARMS INC drugs.

There are thirty-one patent family members on KAI PHARMS INC drugs in twenty-six countries and five supplementary protection certificates in five countries.

Summary for Kai Pharms Inc

International Patents:31
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-002Feb 7, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-002Feb 7, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-002Feb 7, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-002Feb 7, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-001Feb 7, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-001Feb 7, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-003Feb 7, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-001Feb 7, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-001Feb 7, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Kai Pharms Inc
PARSABIV
etelcalcetide
SOLUTION;INTRAVENOUS208325-002Feb 7, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Kai Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,567,370Therapeutic agents for reducing parathyroid hormone levels► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Kai Pharms Inc Drugs

Country Document Number Estimated Expiration
South Africa201200726► Subscribe
European Patent Office2459208► Subscribe
China102711789► Subscribe
Denmark2459208► Subscribe
Japan2013155195► Subscribe
Japan5270799► Subscribe
Brazil112012002143► Subscribe
Slovenia2459208► Subscribe
LithuaniaPA2017007► Subscribe
Singapore10201406921S► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Kai Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0864Netherlands► SubscribePRODUCT NAME: ETELCALCETIDE OF EEN ZOUT DAARVAN, MET INBEGRIP VAN ETELCALCETIDEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1142/001-012 20161115
2017000021Germany► SubscribePRODUCT NAME: ETELCALCETID ODER EIN SALZ DAVON, EINSCHLIESSLICH ETELCALCETIDHYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1142 20161111
0170006 00208Estonia► SubscribePRODUCT NAME: ETELKALTSETIID;REG NO/DATE: EU/1/16/1142 15.11.2016
2017007Lithuania► SubscribePRODUCT NAME: ETELKALCETIDAS ARBA JO DRUSKA, ISKAITANT ETELKALCETIDO HIDROCHLORIDA; REGISTRATION NO/DATE: EU/1/16/1142 20161111
2017 00006Denmark► SubscribePRODUCT NAME: ETELCALCETID ELLER ET SALT DERAF, INKLUSIV ETELCALCETIDHYDROCHLORID; REG. NO/DATE: EU/1/16/1142/001-012 20161115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Julphar
Baxter
Cipla
McKesson
Farmers Insurance
US Department of Justice
Chinese Patent Office
US Army
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot